Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco [UCSF]), Irene Litvan (University of California, San Diego), Julio Rojas (UCSF) and ...

Presentation: A Randomized, Double Blind, Placebo Controlled Study of ATH434 in MSA ...

Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia ...

CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

This milestone builds upon phase one of the virtual clinic ... we can now facilitate clinical research on the HALO™ device while preparing for broader patient adoption. By creating a seamless ...

The first phase of construction is beginning on a new $2.19 billion health care, training and research facility for UNMC and ...

Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines ...

core cohort dose-limiting toxicity observation period in its ongoing Phase 1b/2a clinical trial. Following a review of safety and efficacy data, the Safety Review Committee (SRC) has approved dose ...

George Warren, PhD, Lead Author and Principal Scientist at Artelo, said, "We are excited to share the results on this novel ...

Nexalin Technology (NXL), announced the completion and launch of phases one through ... remote monitoring, and clinical oversight of its HALO headset in both research and patient treatment settings.